Research & Development
The NTx fully recombinant platform allows us to identify and synthesize more novel therapeutics and biologics with a higher degree of efficiency, speed and reproducibility supporting our mission to alleviate the suffering of humanity from disease.
Drug Discovery and Biosynthesis Platform
Our effort is to continually improve and accelerate the integration of our natural product identification (DruID™) and in vitro biosynthesis process (ivt² ™). Recently, we started the transition to a fully recombinant in vitro transcription/translation system, testing and verification is to be completed within a few weeks. Our novel system is thermostable, O2-tolerant and combined with a unique energy-regenerating system which can support ATP supply for days. This system allows significantly longer run times and continuous flow operation. As a recombinant system excludes any form of cellular metabolism, RNAse/DNase or protease activity and unintended posttranslational modification, the reproducibility of in vitro produced biologics is significantly improved.
With this excellent platform, NTx can identify and synthesize novel therapeutics and biologics with a higher degree of efficiency, speed and reproducibility thriving to lift suffering of humanity from disease.
Anti-TB Compounds
Brief description of the compounds and the data obtained so far.
Demonstrated activity in drug-resistant Mycobacterium tuberculosis:
| Activity | MDR strains MIC99 <7.2 μM and <20 μM |
| Efficacy: | Active absorption of compound low µM |
| MOA: | Covalent inhibition of translation initiation (shows remaining activity in Linezolid-resistant strain) |
| Ames test: | Not concentration dependent No significant increase in mutagenesis rate |
| Serum binding: | 20-25% in human and bovine models |
| Cell line toxicity: | No tox. in flow cyt. <20 mg/ml |
| Rodent model: | No immediate toxicity, inflammation or necrosis <80 mg/kg bw (3 isolated doses over 9 days) |
Further activities are demonstrated against:
- Yersinia pestis
- Francisella tularensis
- Klebsiella pneumoniae
- Bacillus anthracis
- Haemophilus influenzae
- Acinetobacter baumannii
New Tetanus Vaccine
NTX-V01
This genetically detoxed tetanus vaccine will not be derived from active clostridium tetani culture, does not require an inactivation with formaldehyde, the currently established method, and has a faster production turn-around cycle when made in vitro.
NTX-V02
A second, improved version of the detoxed tetanus vaccine with different mutations for better solubility and in vitro expression.
Nature’s Toolbox Drug Discovery
NTx’s AI system (DruID™) identifies potential new drug candidates from the vast expanse of biologically active natural products. It will plot the biosynthesis route for using our patented recombinant cell-free system (ivt² ™). Our fully in situ/in vitro approach allows to genetically engineer biosynthetic components of pathways as well as the structure of compounds generating a novel drug discovery pipeline of relevant drug leads that have a high probability for efficacy and safety.
NTx has used their unique drug discovery approach to enable the identification and in vitro biosynthesis of compounds within two important strategic fields:
- A new class of anti-TB leads has been identified and two new anti–bacterial compounds intended for treatment of drug-resistant TB have been synthesized and are currently under initial testing.
- We also focused on the need for faster access to better and safer vaccines and are working to generate a modified and predicted safer version of the world’s most common vaccine against tetanus to potentially replace the existing one.
| Discovery | Non-clinical | Clinical | |||
| Biologics | |||||
| Vaccines | |||||
| Tetanus NTX-V01 | |||||
| Small Molecules | |||||
| Antibacterial | |||||
|
|||||
|